MYC has long been recognized as an undruggable target due to its complex biological functions and structural characteristics [57], making LINC02167 inhibition a potentially feasible alternative strategy, particularly for CRC patients with high MYC expression. The gene discussed is MYC; the disease is colorectal carcinoma.